Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XILLIX FDA APPROVED -- Ignore unavailable to you. Want to Upgrade?

To: Jason Marcotte who wrote (353)	2/3/1999 2:47:00 PM
From: Robert Dydo	Read Replies (1) \| Respond to of 572

The agreement between Miravant and Xillx to develope device allowing a use of Miravan't Photopoint drug as an early stage lung cancer treatment can see a beginning of clinical trails in 1999. I wonder if QLT would be interested or/and Xillix available to make a business combination (due to agreement with Miravant)in this area. One could think that any biotech company working in the area of lung cancer would like to have a device which could actually do what Life-Lung does? Only in USA 600,000 patients with cancer will die this year. More than 1 million people are going to be told by their doctors, “You have cancer”. Conventional therapy (surgery, chemotherapy and radiation) in all cancer patients is only effective in 40 % of the cases. This means that 60% of the patients with cancer will die within five years. Among the patients with advanced cancer, stage III or IV, less than 20% will survive for more than five years. Lung cancer continues as the leading cause of cancer death for both Canadian women and men. Over their lifetimes, 1 in 9 women will develop breast cancer, mainly after age 50; 1 in 16 will develop colorectal cancer; 1 in 21 will develop lung cancer; 1 in 25 will die from breast cancer, and 1 in 24 will die from lung cancer. Among men, approximately 1 in 9 will develop prostate cancer, mainly after age 70. Colorectal cancer will affect 1 in 15; 1 in 11 will develop lung cancer; 1 in 12 will die from lung cancer, and 1 in 27 will die from prostate. Some statistics, Using an early stage screening process wouldn't help those people and save them? Robert